A p-tau217 blood test typically runs between a few hundred and roughly two thousand dollars depending on where and how it is used, though the price you actually pay hinges on insurance coverage, the clinical setting, and whether the test is being used as an initial screen or as a stand-in for a PET scan. The cost picture is shifting fast: the first FDA-approved version reached the U.S. market in mid-2025, and health economists are still working out what the test should cost relative to the expensive imaging and spinal-fluid procedures it could replace. For anyone weighing this test, understanding the sticker price alone misses most of the story.
What the Test Actually Measures
P-tau217 is a form of the tau protein that gets chemically modified (phosphorylated) early in the Alzheimer’s disease process. When amyloid plaques begin accumulating in the brain, p-tau217 levels rise in the blood years before memory symptoms become obvious. Detecting that rise from a simple blood draw is what makes the test valuable: until recently, confirming Alzheimer’s-related brain changes required either a PET scan costing thousands of dollars or a lumbar puncture to collect cerebrospinal fluid, both of which are expensive, uncomfortable, or hard to access in many communities.
On May 16, 2025, the U.S. FDA approved the Lumipulse G blood test, which measures the plasma p-tau217 to amyloid-beta 1-42 ratio, for diagnosing cerebral amyloid plaques in symptomatic patients aged 55 and older.1PubMed Central. Editorial: Real-World Outcomes of Disease-Modifying Therapies Highlight the Need for Diagnostic Biomarkers in Early Alzheimer’s Disease That approval transformed what had been a research-grade marker into a clinically orderable diagnostic, and it immediately raised practical questions about cost, coverage, and who would benefit most.
How Accurate Is the Test
Cost only matters if the test works, and p-tau217 has consistently outperformed other blood-based Alzheimer’s markers. In studies using the automated Lumipulse platform, p-tau217 distinguished amyloid-positive from amyloid-negative patients with an area under the curve of 0.94, compared with 0.88 for both p-tau181 and the amyloid-beta 42/40 ratio.2PubMed Central. Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease A separate real-world validation reported AUC values of 0.94 to 0.97 for identifying patients with confirmed amyloid and tau pathology, again beating other plasma markers.3PubMed. Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer’s disease: a real-world study
Those numbers matter for cost because a highly accurate blood test can reduce unnecessary PET scans and spinal taps. When models integrated p-tau217, they predicted brain amyloid levels with AUC values between roughly 89% and 95% across a wide range of amyloid burden, outperforming cerebrospinal fluid amyloid ratios alone.4PubMed Central. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer’s disease P-tau217 also correlates with tau-PET imaging results, with a correlation of 0.61, particularly in the brain regions most affected by Alzheimer’s.5PubMed Central. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment In practical terms, this means the blood test can often do work that previously required a $3,000-to-$7,000+ PET scan.
How It Compares in Cost to PET Scans and Spinal Taps
The clearest financial argument for p-tau217 testing is what it saves downstream. A cost-effectiveness analysis found that using blood-based biomarker testing as a triage step would identify over 98% of PET-positive patients at a lower average cost per confirmed diagnosis compared with sending everyone straight to PET: about $8,868 per positive diagnosis with the blood-first approach versus $10,345 with PET alone.6PubMed Central. Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer’s disease pathology That roughly 15% reduction in cost per diagnosis adds up quickly across a healthcare system evaluating millions of patients with memory complaints.
An analysis within the Japanese healthcare system found even larger savings, with cost reductions ranging from 34% to 79% compared with PET and up to 74% compared with inpatient cerebrospinal fluid testing, depending on how many patients fell into an intermediate diagnostic zone requiring follow-up.7PubMed Central. Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care system Even in the worst-case scenario in that analysis, where many patients needed confirmatory testing after an ambiguous blood result, costs were roughly comparable to existing methods rather than higher.
The savings come from the “triage” concept. Instead of every patient with cognitive symptoms getting an expensive scan, the blood test filters out those who are clearly negative and flags those who are clearly positive. Only people with borderline results go on to PET or cerebrospinal fluid testing. Researchers have explored “double cutoff” strategies, where two thresholds divide patients into positive, intermediate, and negative groups to further refine this triage and reduce misclassification costs.8PubMed Central. Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms
What Health Economists Think the Test Should Cost
A value-based pricing analysis estimated what the test would be worth based on the downstream procedures it eliminates. When used in primary care as a triage tool, the value-based price came to about $290 per test, because using it at that stage would cut PET use by nearly half and cerebrospinal fluid testing by 86%. When used as a confirmatory test in primary care, replacing PET or spinal taps entirely for most patients, the value-based price jumped to $1,150.9PubMed Central. Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.
In specialty care settings, where patients have already been confirmed to have early-stage cognitive impairment, fewer total blood tests would be ordered but each one displaces more expensive follow-up. The value-based price in that context rose to about $450 for triage and $1,950 for confirmatory use.9PubMed Central. Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S. These figures give you a sense of the range: the “right” price depends heavily on whether the test is being used to screen a broad population or confirm a diagnosis that is already suspected.
Insurance Coverage Is Still Catching Up
One of the biggest frustrations for patients right now is that insurance reimbursement for blood-based Alzheimer’s biomarkers has lagged behind the science. Medicare, which covers most of the population most likely to need this test, has historically covered amyloid PET scans under limited circumstances but has been slower to extend coverage to plasma biomarkers. Private insurers vary widely. Some patients pay out of pocket, and costs in that scenario have typically ranged from around $500 to over $1,200 depending on the specific commercial assay and the lab running it.p>
The FDA approval of the Lumipulse platform in May 2025 is expected to accelerate coverage decisions. FDA clearance often triggers a chain of events: Medicare typically issues a national coverage determination, commercial insurers follow, and diagnostic codes get updated so that labs can bill properly. But that chain takes time, sometimes a year or more. In the interim, some clinicians order the test through research programs or specialty labs that absorb part of the cost, while others ask patients to pay directly and submit for reimbursement after the fact. If you are considering this test today, asking your provider about the specific lab’s cash price and whether any coverage or assistance programs apply is the single most practical step you can take.
Where the Test Is Ordered Matters for Accuracy and Cost
P-tau217 does not perform identically in every clinical setting, and that performance gap has cost implications. In specialty memory clinics, the test showed accuracies of 89% to 91%, with positive predictive values of 89% to 95%. In primary care, accuracy dropped to about 85%, with a positive predictive value of 82%.10PubMed Central. Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform The negative predictive value in primary care was actually quite good at 88%, meaning a negative result reliably rules out Alzheimer’s pathology even outside a specialist’s office.
The difference comes down to what clinicians call “pretest probability.” In a memory clinic, a higher proportion of patients genuinely have Alzheimer’s pathology, so a positive test result is more likely to be a true positive. In a primary care office, where patients present with vaguer complaints and a wider range of possible causes, there are more false positives to contend with. This matters for cost because a false positive sends someone to expensive confirmatory testing they did not need, while a false negative delays diagnosis and treatment. The Alzheimer’s Association’s clinical practice guideline reflects this tension, recommending that blood-based biomarker tests with at least 90% sensitivity and 90% specificity can substitute for PET or cerebrospinal fluid testing, but cautioning that many commercially available tests do not meet those thresholds with a single cutoff and that these tests should be used only as part of a full diagnostic workup in specialized care settings.11PubMed Central. Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings
Kidney Function Can Muddy the Results
One factor that could silently raise your cost is kidney disease. Impaired kidney function elevates p-tau217 concentrations in the blood regardless of whether amyloid plaques are present. A study examining multiple assay platforms found that for every 10-unit worsening in estimated kidney filtration rate, p-tau217 concentrations rose by 12% to 24% depending on the assay used.12Alzheimer’s & Dementia. Effect of kidney function on plasma pTau217 concentrations using different pTau217 assays One version of the test, which uses a ratio of phosphorylated to non-phosphorylated tau, appeared resistant to this effect, but most standard assays are not.
Even mild chronic kidney disease can alter biomarker levels enough to affect test performance. Including kidney function estimates in diagnostic models could help minimize misclassification, but most research so far has focused on mild impairment, leaving gaps in understanding for people with more severe kidney disease.13PubMed Central. Integrating kidney function assessment into the clinical interpretation of plasma Alzheimer’s disease biomarkers Given that chronic kidney disease is common in the same older population most likely to be evaluated for Alzheimer’s, this is not a niche concern. A false positive driven by kidney-related elevation could send you down a path of unnecessary confirmatory imaging, adding thousands of dollars to the total diagnostic cost.
Does the Test Work Equally Well Across Racial and Ethnic Groups
Any test that costs money needs to deliver fair value to everyone paying for it, and the equity picture for p-tau217 is mixed. A large, ethnically diverse memory-clinic study of over 1,100 patients from 91 countries found that p-tau217 concentrations did not differ between ethnic groups and that ethnicity did not influence the test’s diagnostic accuracy for Alzheimer’s pathology.14PubMed Central. Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer’s disease That is reassuring on a biological level.
However, two other studies paint a more nuanced picture. One found that while elevated p-tau217 was associated with cognitive impairment across all racial and ethnic groups studied, discriminative accuracy was modest overall, with the highest performance in non-Hispanic Black participants and the lowest in Hispanic participants.15PubMed Central. Plasma p-tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS-HD Another found that p-tau217 levels were lower in Black/African American participants than in non-Hispanic white participants even after adjusting for cerebrospinal fluid tau, resulting in greater positive predictive value for white participants.16PubMed Central. Influence of cognitive impairment and race on plasma p-Tau217 in two diverse cohorts The researchers suggested this gap might be mediated by differences in complement or lysosomal pathways rather than by differences in Alzheimer’s pathology itself.
The practical cost implication is that a test cutoff calibrated on predominantly white study populations could produce more false negatives in Black patients, potentially delaying diagnosis and access to treatment. Conversely, the large multinational study’s finding that ethnicity did not affect accuracy suggests the issue may be specific to certain assay platforms or population contexts rather than an inherent limitation of measuring p-tau217. Until this is sorted out definitively, awareness of the disparity is worth having, especially if you belong to an underrepresented group and your result comes back borderline.
The Link to Treatment Eligibility
Cost calculations for p-tau217 testing do not exist in a vacuum. The reason this test has become urgent is that new anti-amyloid therapies, such as lecanemab and donanemab, require confirmation of brain amyloid before treatment can begin. Without that confirmation, you cannot receive the drug. Previously, getting that confirmation meant a PET scan or lumbar puncture. A blood test that accurately identifies amyloid-positive patients could dramatically expand the number of people who can be evaluated and, if appropriate, start treatment.
This creates a financial feedback loop. The more patients who are screened with a relatively cheap blood test, the more patients are identified as candidates for treatments that themselves cost tens of thousands of dollars per year. Health systems need to plan for the total cost of the diagnostic-to-treatment pipeline, not just the cost of the blood draw. That said, the alternative, leaving Alzheimer’s undiagnosed or diagnosed late, carries its own enormous financial burden in caregiver costs, emergency care, and institutional placement. The blood test sits at the front end of that entire chain.
Long-Term Care Insurance and Biomarker Results
A cost that rarely appears in medical pricing discussions is the potential financial exposure from having a biomarker result in your medical record. Research into the legal protections around Alzheimer’s biomarker testing found that while individuals who learn their biomarker status are generally protected from adverse health insurance coverage decisions (thanks to laws like the Affordable Care Act), they are not meaningfully protected from adverse long-term care insurance underwriting decisions.17The Journal of Law, Medicine & Ethics. The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer’s Disease Biomarkers Long-term care insurers are permitted to use medical underwriting, and a positive amyloid biomarker result could make it harder or more expensive to obtain coverage.
This does not mean you should avoid testing. It does mean that if you are considering purchasing long-term care insurance, the timing relative to biomarker testing is worth thinking about. A positive p-tau217 result that enters your medical record before you apply for long-term care coverage could affect your premiums or eligibility, even if you have no symptoms. This is a gap in consumer protection that predates blood-based testing but becomes more consequential now that testing is cheaper and easier to obtain. Discussing the implications with both a physician and a financial advisor before ordering the test is a reasonable precaution for anyone in the relevant age range who does not already hold long-term care insurance.
The Assay Platform Matters More Than You Might Expect
Not all p-tau217 tests are the same product. Multiple companies offer different assay platforms that measure the same protein but use different antibodies, calibration methods, and cutoff values. The FDA-approved Lumipulse G test is one platform; C2N Diagnostics’ PrecivityAD2 and Janssen/Fujirebio’s offerings are others. These platforms do not always agree on whether a given patient falls above or below the diagnostic threshold. Research comparing double-cutoff strategies across assay platforms found that accuracy gains were modest but that the cost implications varied substantially by platform, with some assays reducing costs in most settings and others actually increasing them.8PubMed Central. Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms
For you as a patient, this means the specific lab your doctor sends the blood to could influence both your result and your bill. An assay that produces more intermediate or ambiguous results will push more patients toward confirmatory PET scans, adding to the total cost of reaching a diagnosis. Asking your physician which platform is being used and whether it has been validated in a clinical population similar to yours is a reasonable question, even if the answer is technical. The practical difference between an assay with a 5% intermediate zone and one with a 20% intermediate zone could be the difference between a $300 blood test settling the question and a $300 blood test followed by a $5,000 PET scan.